about
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...
Read More
15.46
-0.27
(-1.72%)
646.8K
XNAS Volume
XNAS 08 Aug, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Immunovant Inc is on 13 Aug 2025 for the purpose of Immunovant Inc First Quarter Earnings Results for 2025
See details
Not Eligible
Expensive Valuation
Technically Bearish
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..